[go: up one dir, main page]

PL3763718T3 - Podstawiony 3,4,12,12a-tetrahydro-1H-[1,4]oksazyno[3,4-c]pirydo[2,1-f][1,2,4]triazyno-6,8-dion, kompozycja farmaceutyczna oraz sposoby jej wytwarzania i zastosowania - Google Patents

Podstawiony 3,4,12,12a-tetrahydro-1H-[1,4]oksazyno[3,4-c]pirydo[2,1-f][1,2,4]triazyno-6,8-dion, kompozycja farmaceutyczna oraz sposoby jej wytwarzania i zastosowania

Info

Publication number
PL3763718T3
PL3763718T3 PL20781429.4T PL20781429T PL3763718T3 PL 3763718 T3 PL3763718 T3 PL 3763718T3 PL 20781429 T PL20781429 T PL 20781429T PL 3763718 T3 PL3763718 T3 PL 3763718T3
Authority
PL
Poland
Prior art keywords
oxazino
pyrido
dione
tetrahydro
triazine
Prior art date
Application number
PL20781429.4T
Other languages
English (en)
Inventor
Oleg Dmitrievich Mitkin
Alexandre Vasilievich IVACHTCHENKO
Andrey Alexandrovich Ivashchenko
Original Assignee
Viriom, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viriom, Inc. filed Critical Viriom, Inc.
Publication of PL3763718T3 publication Critical patent/PL3763718T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL20781429.4T 2019-05-07 2020-03-27 Podstawiony 3,4,12,12a-tetrahydro-1H-[1,4]oksazyno[3,4-c]pirydo[2,1-f][1,2,4]triazyno-6,8-dion, kompozycja farmaceutyczna oraz sposoby jej wytwarzania i zastosowania PL3763718T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2019113751A RU2720305C1 (ru) 2019-05-07 2019-05-07 Замещенный 3,4,12,12а-тетрагидро-1Н-[1,4]оксазино[3,4-c]пиридо[2,1-f] [1,2,4]триазин-6,8-дион, фармацевтическая композиция, способы их получения и применения
PCT/RU2020/000163 WO2020226532A1 (ru) 2019-05-07 2020-03-27 ЗАМЕЩЕННЫЙ 3,4,12,12А-ТЕТРАГИДРО-1Н-[1,4]ОКСАЗИНО[3,4-С]ПИРИДО[2,1-f] [1,2,4]ТРИАЗИН- 6,8-ДИОН, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ

Publications (1)

Publication Number Publication Date
PL3763718T3 true PL3763718T3 (pl) 2025-05-26

Family

ID=70553085

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20781429.4T PL3763718T3 (pl) 2019-05-07 2020-03-27 Podstawiony 3,4,12,12a-tetrahydro-1H-[1,4]oksazyno[3,4-c]pirydo[2,1-f][1,2,4]triazyno-6,8-dion, kompozycja farmaceutyczna oraz sposoby jej wytwarzania i zastosowania

Country Status (19)

Country Link
US (3) US12091423B2 (pl)
EP (1) EP3763718B8 (pl)
JP (1) JP7625527B2 (pl)
CN (1) CN112204035A (pl)
AU (1) AU2020269125A1 (pl)
CA (1) CA3106620A1 (pl)
DK (1) DK3763718T3 (pl)
EA (1) EA202190324A1 (pl)
ES (1) ES3018631T3 (pl)
FI (1) FI3763718T3 (pl)
HR (1) HRP20250317T1 (pl)
HU (1) HUE071356T2 (pl)
LT (1) LT3763718T (pl)
PL (1) PL3763718T3 (pl)
PT (1) PT3763718T (pl)
RS (1) RS66803B1 (pl)
RU (1) RU2720305C1 (pl)
SI (1) SI3763718T1 (pl)
WO (1) WO2020226532A1 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2745985C1 (ru) * 2020-05-07 2021-04-05 Андрей Александрович Иващенко Антикоронавирусный терапевтический агент - замещенный 7-гидрокси-3,4,12,12а-тетрагидро-1H-[1,4]оксазино[3,4-c]пиридо[2,1-f][1,2,4]триазин-6,8-дион для профилактики и лечения COVID-19
CN116284046B (zh) * 2023-02-22 2025-11-11 山东新华制药股份有限公司 巴洛沙韦衍生物及其制备方法和应用
CN119841849B (zh) * 2024-09-26 2025-08-15 浙江大学 一种吡啶酮类化合物、合成方法及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20181250T1 (hr) * 2010-09-24 2018-10-05 Shionogi & Co., Ltd. Predlijek iz supstituiranog policikličkog derivata karbamoilpiridona
CA2953862A1 (en) * 2014-07-07 2016-01-14 F. Hoffmann-La Roche Ag Dihydropyridopyrazine-1,8-diones and their use in the treatment, amelioration or prevention of viral diseases
AU2016256125B9 (en) * 2015-04-28 2020-02-20 Shionogi And Co., Ltd. Substituted polycyclic pyridone derivative and prodrug thereof
PL3290424T3 (pl) * 2015-04-28 2023-05-08 Shionogi & Co., Ltd Podstawione policykliczne pochodne pirydonu i ich prolek
JP6806413B2 (ja) * 2016-02-03 2021-01-06 塩野義製薬株式会社 多環性ピリドン誘導体およびそのプロドラッグ
KR20190007517A (ko) * 2016-08-10 2019-01-22 시오노기세야쿠 가부시키가이샤 치환된 다환성 피리돈 유도체 및 그의 프로드러그를 함유하는 의약 조성물
WO2019052565A1 (zh) 2017-09-18 2019-03-21 广东东阳光药业有限公司 流感病毒复制抑制剂及其用途
CN109503625A (zh) * 2018-01-19 2019-03-22 赵蕾 一种多环吡啶酮化合物及其药物组合和用途
CN112778330A (zh) * 2019-11-05 2021-05-11 上海翰森生物医药科技有限公司 含吡啶酮多环类衍生物抑制剂、其制备方法和应用

Also Published As

Publication number Publication date
SI3763718T1 (sl) 2025-06-30
ES3018631T3 (es) 2025-05-16
RS66803B1 (sr) 2025-06-30
CA3106620A1 (en) 2020-11-12
EA202190324A1 (ru) 2021-05-18
PT3763718T (pt) 2025-03-14
US20220048925A1 (en) 2022-02-17
EP3763718A4 (en) 2021-11-17
EP3763718B1 (en) 2025-02-26
JP2022539939A (ja) 2022-09-14
US20240383919A1 (en) 2024-11-21
JP7625527B2 (ja) 2025-02-03
WO2020226532A1 (ru) 2020-11-12
HRP20250317T1 (hr) 2025-05-09
CN112204035A (zh) 2021-01-08
LT3763718T (lt) 2025-05-12
DK3763718T3 (da) 2025-03-24
RU2720305C1 (ru) 2020-04-28
EP3763718B8 (en) 2025-04-09
HUE071356T2 (hu) 2025-08-28
US12091423B2 (en) 2024-09-17
FI3763718T3 (fi) 2025-04-01
EP3763718A1 (en) 2021-01-13
US20240383918A1 (en) 2024-11-21
AU2020269125A1 (en) 2021-02-11

Similar Documents

Publication Publication Date Title
IL285315B2 (en) Imidazo[F-2,1][4,2,1]triazine-4-amine derivatives as TLR7 agonists
MX2021014674A (es) Pirrolo [2,3-b] piridina sustituida y derivados de pirazolo [3,4-b] piridina como inhibidores de proteinas quinasas.
EP4056571A4 (en) TRICYCLIC DIHYDROIMIDAZOPYRIMIDONE DERIVATIVE, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF
HUE063367T2 (hu) 2,3-Dihidro-1H -pirrolo[3,4-c]piridin-1-on származékok mint HPK1 inhibitorok, rák kezelésére
PL3763718T3 (pl) Podstawiony 3,4,12,12a-tetrahydro-1H-[1,4]oksazyno[3,4-c]pirydo[2,1-f][1,2,4]triazyno-6,8-dion, kompozycja farmaceutyczna oraz sposoby jej wytwarzania i zastosowania
LT3500571T (lt) Imidazo[1,2-a]piridino junginiai, juos apimančios kompozicijos, ligų gydymo būdai juos panaudojant, ir jų paruošimo būdai
IL290445A (en) [4,2,1]triazolo[5,1-c]quinazoline-5-amines
EP3750891A4 (en) PYRAZOLO [1,5-A] [1,3,5] TRIAZINE-2-AMINE DERIVATIVE, METHOD OF PREPARATION AND MEDICAL USE
ZA202100259B (en) Pyrrolo[1,2-b]pyridazine derivatives
EP3395817A4 (en) PYRIDO [1,2-A] PYRIMIDONE ANALOGON, CRYSTAL FORM THEREOF, INTERMEDIATE PRODUCT AND MANUFACTURING METHOD THEREFOR
IL281030A (en) Polymorph crystal of 8-bromo-2-(1-methylpyridin-4-ylamino)-4-(4-phenoxyphenylamino)pyrido[D-4,3] pyrimidine-5 (H6)-one hydrochloride and methods for its preparation
IL280513A (en) Imidazo[2,1-B]pyridazines as TRK inhibitors
IL280122A (en) Imidazo[2,1-B]pyridazine derivatives as TRK inhibitors
ZA202409227B (en) Imidazopyridazine substituted benzene ring derivative, preparation method, pharmaceutical composition and use
MY203494A (en) 6h-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivative
ZA202211414B (en) Naphthyridine and pyrido[3,4-c]pyridazine derivatives as gabaa α5 receptor modulators
HK40063512A (en) Imidazo [2, 1-f] [1, 2, 4] triazin-4-amine derivatives as tlr7 agonist
HK40095835A (zh) 制备咪唑并[1，2-a]吡咯并[2，3-e]吡嗪类化合物及其固态形式的方法
HK40067301A (zh) 取代的吡唑并[4，3-b]吡啶及其作为glun2b受体调节剂的用途
HK40123129A (zh) 新型吡啶并[1，2-a]嘧啶-4-酮衍生物、其制剂及制备方法
HK40055110A (en) Pyrrolo[1,2-b]pyridazine derivatives as irak4 inhibitors
HK40055108A (en) Pyrrolo[1,2-b]pyridazine derivatives as irak4 inhibitors